Physician profile
Andrew Christopher Nutting
NPI 1386107068
$2,315.22
in general payments reported to CMS, 2019-2025
19 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.52 · 2022: $22.56 · 2023: $456 · 2024: $803 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.18 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $306.12 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Pfizer INC. | $304.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.22 | 2023-2025 | Ofev |
| Merck Sharp & Dohme LLC | $170.11 | 2021-2025 | Zerbaxa, Winrevair, Recarbrio |
| Genzyme Corporation | $169.70 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $158.19 | 2023-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $156.79 | 2023-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $127.97 | 2023-2025 | Uptravi, Opsumit |
| La Jolla Pharmaceutical Company | $71.17 | 2024-2025 | Giapreza |
| Bayer Healthcare Pharmaceuticals INC. | $54.04 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.79 | 2025 | Glassia |
| Janssen Pharmaceuticals, INC | $38.95 | 2024 | Xarelto |
| Inari Medical, INC. | $25.49 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $22.56 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $21.48 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $21.29 | 2025 | Tyvaso |
| Grifols USA, LLC | $16.11 | 2025 | Prolastin-C Liquid |
| Insmed, INC. | $13.92 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Nutting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.